Camber Capital Management LLC
Q1 2014 13F-HR Holdings
Net value change ($000)
+142,324
(12.6%)
New positions
9
Sold out positions
6
Turnover %
30.8%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| HAE | 39,173 | NEW |
| LH | 36,829 | NEW |
| CYH | 29,327 | 149.4% |
| THC | 26,445 | 57.1% |
| HRC | 23,124 | NEW |
| ABT | 23,106 | NEW |
| KERYX BIOPHARMACEUTICALS | 21,300 | NEW |
| DGX | 20,880 | 48.7% |
| GENOMIC HEALTH INC | 19,755 | NEW |
| FURIEX PHARMA INC | 13,050 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| MYLAN INC | -63,743 | -83.9% |
| MRK | -49,565 | -100.0% |
| A | -28,595 | -100.0% |
| UNH | -24,348 | -49.7% |
| EW | -23,016 | -100.0% |
| HUM | -18,744 | -45.4% |
| HCA | -17,637 | -29.6% |
| Arrowhead Pharma Inc | -16,275 | -100.0% |
| CCRN | -12,879 | -83.8% |
| ARIAD PHARMACEUTICALS INC | -11,625 | -32.5% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
233,763
(18.3% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|